Zabdeno Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The zabdeno market research report is one of a series of new reports that provides zabdeno market statistics, including zabdeno industry global market size, regional shares, competitors with a zabdeno market share, detailed zabdeno market segments, market trends, and opportunities, and any further data you may need to thrive in the zabdeno industry. This zabdeno market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The growth in the forecast increased funding for global health initiatives, expansion of vaccine distribution networks, ongoing research and development in vaccine efficacy, support from international health organizations, growing demand for rapid response vaccines. Major trends include the growth in public-private partnerships, expansion of regional vaccine production, advancements in vaccine storage and transportation, increased focus on pandemic preparedness, integration of digital health solutions for vaccine tracking.

The growing number of Ebola virus disease cases is expected to drive the expansion of the Zabdeno market. Ebola virus disease (EVD), also known simply as Ebola, is a severe and often fatal illness caused by the Ebola virus, which is part of the Filoviridae family. The rise in Ebola cases can be attributed to factors such as increased interactions between humans and wildlife, as well as inadequate surveillance and containment measures in high-risk areas, which facilitate the virus's spread. Zabdeno, a vaccine developed to combat Ebola, helps protect individuals by stimulating the immune system to recognize and fight the virus, thereby reducing the risk of infection and potentially preventing severe symptoms. For example, in January 2023, the World Health Organization reported around 164 Ebola cases (142 confirmed, 22 probable), with 77 deaths (55 among confirmed cases and 22 among probable cases), and 87 recoveries. As a result, the rising incidence of Ebola virus disease is fueling the growth of the Zabdeno market.

The growth of immunization programs is expected to further drive the Zabdeno market. Immunization programs are public health initiatives designed to protect individuals and populations from infectious diseases through vaccination. The expansion of these programs is due to the growing recognition of their effectiveness in preventing the spread of diseases and improving global vaccination coverage. Immunization programs enhance the reach and effectiveness of Zabdeno by providing widespread protection, reducing the disease burden, boosting herd immunity, and contributing to healthier populations. This, in turn, allows Zabdeno to play a more significant role in improving public health outcomes. For instance, in April 2024, the Centers for Disease Control and Prevention reported that the International Coordinating Group’s Ebola vaccine stockpile had increased from 500,000 doses in 2022 to 518,890 doses in December 2023, reflecting a 3.8% growth in one year. Therefore, the expansion of immunization programs is driving the growth of the Zabdeno market.

Strategic partnerships are playing a crucial role in expanding the distribution and accessibility of Zabdeno, particularly in regions heavily affected by Ebola. These partnerships help strengthen efforts to combat Ebola outbreaks through coordinated public health initiatives, allowing for more efficient vaccine deployment. By mobilizing resources, sharing expertise, and coordinating actions, these partnerships contribute to containing outbreaks and saving lives. For example, Johnson & Johnson, a company that develops Zabdeno, collaborated with the World Health Organization to support the distribution of the Ebola vaccine in countries impacted by the disease, especially in Africa. This partnership aims to prevent further Ebola transmission by establishing a protective barrier against the virus, starting in Sierra Leone and potentially expanding to other countries in the region.

The key company operating in the zabdeno market is Johnson & Johnson Inc.

North America was the largest region in the zabdeno market in 2024. The regions covered in zabdeno report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the zabdeno market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Zabdeno is a combination vaccine designed to protect against Ebola virus disease. It contains two components: one targeting the Zaire ebolavirus and the other targeting the Sudan ebolavirus. Administered as a two-dose regimen, Zabdeno is used for pre-exposure prophylaxis in individuals at high risk of Ebola virus exposure, serving as a vital tool in preventing outbreaks.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The main types of zabdeno are single-dose and two-dose vaccines. Single-dose vaccines offer rapid and effective protection against Ebola virus disease with just one shot, helping to control outbreaks, particularly in high-risk areas. This vaccine is used to prevent Ebola virus disease and is distributed through various channels such as hospitals, clinics, retail pharmacies, online pharmacies, and wholesale distribution. It is utilized by various end users, including adults and the elderly.

The zabdeno market consists of sales of zabdeno (Ad26.ZEBOV) and mvabea (MVA-BN-Filo). Values in this market are ‘factory gate’ values, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.